CellaVision AB (publ) Interim report: January 1 - June 30, 2011
(Thomson Reuters ONE) -
Continued sales growth in all markets
January 1 - June 30, 2011
* Net sales rose by 26 % to SEK 72.5 million (57.8).
* Operating profit was SEK 7.1 million (2.7).
* Profit before tax was SEK 4.8 million (3.4)
* Earnings per share were SEK 0.10 (0.14).
* Cash and cash equivalents at the end of the period were SEK 42.7 million
(25.1).
April 1 - June 30, 2011
* Net sales increased by 14 % to SEK 41.9 million (36.6).
* The operating result was SEK 4.7 million (7.1)
* Profit before tax was SEK 4.5million (8.0).
* Earnings per share were SEK 0.09 (0.34).
CellaVision in brief
(SEK million) April-June April-June Jan-June Jan-June Full year
2011 2010 2011 2010 2010
Net sales 41.9 36.6 72.5 57.8 131.6
Gross profit 25.7 26.8 46.5 40.8 87.6
Operating profit 4.7 7.1 7.1 2.7 13.9
Profit before tax 4.5 8.0 4.8 3.4 10.7
Cash flow 2.5 7.1 6.9 3.1 13.8
CellaVision's CEO comments: Continuing strong demand enables us to develop and
invest for the future
"The strong drivers for increased effectiveness in our markets remain, and
demand for our products continues to increase. Sales in the first six months of
the year rose by 26 per cent and accordingly total sales were just over SEK 72
million, compared with SEK 58 million in the same period last year.
Our sales successes in all markets are continuing, parallel sales channels are
showing a positive trend in the US, demand for our analyzer for mid-size
laboratories, CellaVision DM1200, is increasing in the European market and
interest in our products continues to grow in China, Hong Kong and South-East
Asia.
Continuing strong demand enables us to develop and invest for the future. Our
new product idea, which will give collaborating laboratories and hospital groups
the possibility of using CellaVision's technology even in small laboratories,
was evaluated by customers during the spring with positive results. We plan to
present a final product before the end of the year.
In July our contract manufacturer will move production to another site. The
situation will temporarily entail longer delivery times to customers but will
most likely not mean lost orders. We expect that production will be up and
running in September and thereafter improve our ability to meet expected growth.
Achieving a stable rate of output, adapted to higher sales targets, is part of
our long-term growth strategy."
Yvonne Mårtensson, CEO, CellaVision AB
Questions concerning the report can be addressed to:
Yvonne Mårtensson, CEO cell: +46 708 33 77 82,
email:yvonne.martensson(at)cellavision.se
Johan Wennerholm, CFO celll: +46 708 33 81 68,
email:johan.wennerholm(at)cellavision.se
CellaVision AB (publ) Interim report: January 1 - June 30, 2011:
http://hugin.info/132164/R/1531034/465946.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1531034]
Unternehmensinformation / Kurzprofil:
Datum: 15.07.2011 - 08:32 Uhr
Sprache: Deutsch
News-ID 56426
Anzahl Zeichen: 4062
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 183 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision AB (publ) Interim report: January 1 - June 30, 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
